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ABSTRACT
Introduction Early detection and treatment of diabetes 
as well as its prevention help lessen longer- term 
complications. We determined the prevalence of pre- 
diabetes and undiagnosed diabetes in the UK Biobank and 
standardized the results to the UK general population.
Research design and methods This cross- sectional 
study analyzed baseline UK Biobank data on plasma 
glycated hemoglobin (HbA1c) to compare the prevalence of 
pre- diabetes and undiagnosed diabetes mellitus in white, 
South Asian, black, and Chinese participants. The overall 
and ethnic- specific results were standardized to the UK 
general population aged 40–70 years of age.
Results Within the UK Biobank, the overall crude 
prevalence was 3.6% for pre- diabetes, 0.8% for 
undiagnosed diabetes, and 4.4% for either. Following 
standardization to the UK general population, the results 
were similar at 3.8%, 0.8%, and 4.7%, respectively. Crude 
prevalence was much higher in South Asian (11.0% pre- 
diabetes; 3.6% undiagnosed diabetes; 14.6% either) or 
black (13.8% pre- diabetes; 3.0% undiagnosed diabetes; 
16.8% either) participants. Only six middle- aged or old- 
aged South Asian individuals or seven black would need to 
be tested to identify an HbA1c result that merits action.
Conclusions Single- stage population screening for pre- 
diabetes or undiagnosed diabetes in middle- old or old- 
aged South Asian and black individuals using HbA1c could 
be efficient and should be considered.
INTRODUCTION
The prevalence of diabetes is rising world-
wide, particularly in low- income and middle- 
income countries.1 Diabetes has long been 
recognized as a major cause of morbidity 
and mortality. Most recently, diabetes has 
been identified as a risk factor for adverse 
COVID-19 outcomes, including hospitaliza-
tion and death.2 3 In 2017, it was estimated 
that the global prevalence of pre- diabetes was 
7.7% and 4.2% for undiagnosed diabetes.4 
It is predicted that these numbers will rise 
significantly by 2045.4
There is now clear evidence that people 
with pre- diabetes are not just at elevated 
risk of developing diabetes but also at risk of 
adverse cardiovascular outcomes.5 Lifestyle 
changes and metformin can prevent progres-
sion to diabetes,6 and diabetes prevention 
programs now operate in many countries, 
including the UK.7 However, the scale of pre- 
diabetes and undiagnosed diabetes and the 
best way to identify people with these condi-
tions are currently unclear.
The aim of the current study was to deter-
mine the prevalence of pre- diabetes and 
undiagnosed diabetes by ethnic group and 
the average number of people who would 
need to undergo testing to identify each case.
Significance of this study
What is already known about this subject?
 ► Diabetes prevention programs now operate in many 
countries, including the UK.
 ► How to efficiently screen for people at elevated risk 
and in different ethnicities remains uncertain.
What are the new findings?
 ► Overall, we estimate 1 in 22 (4.7%) of individuals 
aged 40–70 years old in the UK have actionable gly-
cated hemoglobin (HbA1c) concentrations.
 ► This prevalence is markedly higher in minority ethnic 
groups.
 ► 1 in 6–7 individuals of black or South Asian ethnicity 
have actionable values and approximately 1 in 30 
are living with undiagnosed diabetes.
How might these results change the focus of 
research or clinical practice?
 ► HbA1c could be used to identify pre- diabetes and 
undiagnosed diabetes in middle- old and old- aged 
South Asian and black individuals without the need 
for prior risk scoring.
 ► Similar work is now needed in other countries.
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RESEARCH DESIGN AND METHODS
This study used data from the UK Biobank (https://www. 
ukbiobank. ac. uk/). The UK Biobank is a large general 
population cohort of 502 624 middle- aged or older- aged 
participants (40–69 years old at recruitment) who were 
recruited at 22 centers across the UK between March 
2006 and December 2010.8 During recruitment, partic-
ipants provided detailed demographic, lifestyle and 
medical history information and biological samples, and 
anthropometric measurements were taken. Inclusion 
in this study was restricted to participants who identi-
fied themselves as white, Indian, Pakistani, Bangladeshi, 
black African, black Caribbean, or Chinese. To provide 
sufficient statistical power, Indian, Pakistani, and Bangla-
deshi participants were amalgamated into South Asian, 
and black African and black Caribbean participants were 
amalgamated into black.
All participants gave written informed consent before 
enrollment in the study.
Deprivation status was based on the Townsend Depri-
vation Index derived from the postcode of residence 
at recruitment. Body mass index (BMI) was calculated 
from weight/height2 and categorized into underweight 
(<18.5 kg/m2), normal weight (18.5–24.9 kg/m2), over-
weight (25.0–29.9 kg/m2), and obese (≥30.0 kg/m2), 
according to the WHO classification. A lifestyle score, 
previously shown to be associated with all- cause mortality, 
was used to characterize overall lifestyle as described 
previously.9 10 Lifestyle factors, self- reported at baseline, 
included smoking status (current, former, or never), 
physical activity (time spent doing moderate and vigorous 
physical activity per week, converted to metabolic equiv-
alents (METs)- min/week and dichotomized into inactive 
(<600 METs- min/week) and active (≥600 METs- min/
week) according to the physical activity guidelines11), 
sedentary time (watching television, using a computer, 
and non- work- related driving), adequate sleep, and 
optimal dietary intake of fruit and vegetables (≥5/day), 
red meat (<70 g/day) and processed meat (never or less 
than once a week), oily fish (≥1/week), and alcohol (<14 
units/week). The overall lifestyle score ranged from 
0 (most unhealthy; highest risk of all- cause mortality) 
to 9 (most healthy; lowest risk of all- cause mortality). 
Sampling procedures for UK Biobank biomarkers have 
been described and validated previously.12 13 Briefly, 
biochemistry analyses were performed at a dedicated 
central laboratory on 480 000 samples between 2014 and 
2017 and included plasma glycated hemoglobin (HbA1c) 
(VARIANT II TURBO Hemoglobin Testing System; Bio- 
Rad). Data were adjusted for preanalytical variables by 
the UK Biobank centrally before release.
Known diabetes was defined as at least one of the 
following: type 1 or type 2 diabetes self- reported by the 
participant at baseline and/or taking insulin or other 
diabetes- related medications (metformin, sulfonylurea, 
meglitinides/glinides/prandial glucose regulators, alpha- 
glucosidase inhibitors, thiazolidinedione/glitazones, 
dipeptidyl peptidase-4 (DPP-4) inhibitors/gliptins, incretin 
mimetics/glucagon- like peptide-1 (GLP-1) analogs, and 
amylin analogs). Participants with known diabetes were 
excluded from the study. Among the remaining partici-
pants, pre- diabetes and undiagnosed diabetes were ascer-
tained from HbA1c concentrations and defined as HbA1c 
42–47.9 mmol/mol and ≥48 mmol/mol, respectively.14
Sensitivity analyses were conducted excluding partic-
ipants with self- reported cardiovascular disease at base-
line (heart attack, angina, stroke, or transient ischemic 
attack), since such individuals are likely to be already 
in receipt of preventive pharmaceutical or lifestyle 
interventions.
Participants were stratified by ethnicity and sex and 
their baseline characteristics summarized using percent-
ages for categorical variables and mean and SD, or 
median and IQR, for continuous variables. Crude prev-
alence was calculated by dividing the total number of 
cases by the total number of the population in each cate-
gory. Crude prevalence was derived overall and by age, 
gender, and ethnic subgroup. The 2011 Census data15 
were used to standardize the prevalence rates to the age, 
gender, and ethnic breakdown of the UK general popula-
tion, within the age group recruited to the UK Biobank. 
Briefly, sex- specifc and ethnic- specific prevalence rates 
obtained from the UK Biobank were used to estimate the 
total cases in the UK general population, according to 
the total of men and women in each of the ethnic group 
in the 40–70 age group only, and the corresponding 
UK population prevalence rates for all 40–70 years old 
were recalculated. The yield (average number needed to 
test to detect a case) was derived from inversion of the 
prevalence.
RESULTS
UK Biobank participants who had missing data on HbA1c 
(n=36 135), had known diabetes at baseline (n=24 593), 
or classified themselves as mixed or other ethnic group 
(n=8081) were excluded from the study. The resultant 
study population comprised 433 856 participants: 419 512 
(96.7%) white, 7400 (1.7%) South Asian, 5578 (1.3%) 
black, and 1366 (0.3%) Chinese. This compared with 
94.0%, 3.2%, 2.4%, and 0.5%, respectively, in the UK 
general population within the same age range. White 
participants were older, black participants were more 
likely to live in the most deprived areas, and black women 
had the highest BMI (table 1). Lifestyle score was higher 
(healthier) among women than men but did not differ 
significantly by ethnic group.
Overall, the crude prevalence was 3.6% for pre- 
diabetes, 0.8% for undiagnosed diabetes, and 4.4% for 
either (table 2). However, there were wide variations by 
ethnic group. The prevalence of pre- diabetes was only 
3.3% among white participants compared with 11.0% 
and 13.8% in South Asian and black, respectively. Simi-
larly, only 0.7% of white participants had undiagnosed 
diabetes compared with 3.6% of South Asian and 3.0% 
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of black participants. As a result, 25 white participants 
would need to be tested to identify one case of either 
pre- diabetes or undiagnosed diabetes compared with 
only 7 South Asian participants or 6 black participants. 
Standardization against the UK general population in 
the same age range made little difference to the overall 
or ethnic- specific results (table 3).
When the results were recalculated for age and sex 
subgroups within each ethnicity group, there was a 
consistent trend in white and South Asian participants, 
whereby the prevalence of pre- diabetes or undiagnosed 
diabetes was higher in men than in women and increased 
with increasing age (tables 4 and 5). Among South Asian 
or black men over 55 years of age, only three to five indi-
viduals needed to be tested to identify an actionable 
HbA1c value.
The sensitivity analyses, which excluded 22 873 partic-
ipants with self- reported cardiovascular disease at base-
line, made little meaningful difference to the prevalence 
rates or the average number needed to be tested to 
identify cases both overall and by ethnic group (online 
supplemental table S1).
To investigate the impact of the characteristics that 
differed among the included ethnic groups on their 
increased risk of pre- diabetes and undiagnosed diabetes, 
we ran logistic regression models unadjusted and adjusted 
for sociodemographic variables (sex, age, deprivation) and 
lifestyle (lifestyle score). All ethnic groups had a much 
stronger risk of pre- diabetes or undiagnosed diabetes than 
white participants. After adjustment, the risk of both pre- 
diabetes and undiagnosed diabetes became even stronger 
for all ethnic groups but black participants, where it attenu-
ated slightly (online supplemental table S2).
CONCLUSIONS
Our findings suggest that 1 in 22 (4.7%) of individuals 
aged 40–70 years old in the UK have actionable HbA1c 
concentrations. More importantly, 1 in 6–7 individuals 


























Pre- diabetes 13 844
3.3 (3.3 to 3.4)
815
11.0 (10.3 to 11.8)
770
13.8 (12.9 to 14.7)
106
7.8 (6.5 to 9.3)
15 535




0.7 (0.7 to 0.7)
263
3.6 (3.2 to 4.0)
167
3.0 (2.6 to 3.5)
15
1.1 (0.7 to 1.8)
3346
0.8 (0.8 to 0.8)
Pre- diabetes or 
undiagnosed diabetes
16 745
4.0 (3.9 to 4.1)
1078
14.6 (13.5 to 15.8)
937
16.8 (15.5 to 18.2)
121
8.9 (7.1 to 11.1)
18 881
4.4 (4.3 to 4.4)
  Yield Yield Yield Yield Yield
Pre- diabetes 1 in 30 1 in 9 1 in 7 1 in 13 1 in 28
Undiagnosed 
diabetes
1 in 143 1 in 28 1 in 33 1 in 91 1 in 130
Pre- diabetes or 
undiagnosed diabetes
1 in 25 1 in 7 1 in 6 1 in 11 1 in 23
Yield refers to the average number needing to be tested to identify one case.
HbA1c, glycated hemoglobin; n, number.
Table 3 Prevalence of pre- diabetes and undiagnosed diabetes and yield of HbA1c by ethnic group standardized* to the UK 













n (%) n (%) n (%) n (%) n (%) Yield
Pre- diabetes 795 965 (3.3) 89 859 (11.0) 83 151 (13.8) 9112 (7.8) 978 087 (3.8) 1 in 26
Undiagnosed diabetes 166 794 (0.7) 28 997 (3.6) 18 034 (3.0) 1290 (1.1) 215 115 (0.8) 1 in 125
Pre- diabetes or undiagnosed 
diabetes
962 759 (4.0) 118 856 (14.6) 101 185 (16.8) 10 402 (8.9) 1 193 202 (4.7) 1 in 22
Yield refers to the average number needing to be tested to identify one case.
*Ethnic- specific results standardized by age and sex; overall results standardized by age, sex, and ethnic group.
HbA1c, glycated hemoglobin; n, number.
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of black or South Asian ethnicity have actionable 
values and approximately 1 in 30 are living with undi-
agnosed diabetes. The risk of having pre- diabetes or 
undiagnosed diabetes is magnified by older age, male 
sex, living in deprived areas, and having unhealthy 
lifestyle. Given that diabetes prevention programs are 
now increasingly well developed, including the English 
program,7 these data suggest that screening based on 
ethnicity and age would be extremely efficient at identi-
fying people at high risk of developing type 2 diabetes. 
For white individuals, needing to test 25 individuals to 
detect an actionable HbA1c value suggests a two- stage 
process may be more cost- effective, in line with the 
current National Institute for Health and Care Excel-
lence guidelines,16 with the first stage being a simple 
risk score (which could easily be self- completed). Such 
Table 4 Crude prevalence of pre- diabetes and undiagnosed diabetes and crude yield of HbA1c in the UK Biobank in women 
by age and ethnic group
White
(n by age group)
South Asian
(n by age group)
Black
(n by age group)
Chinese
(n by age group)
Overall
(n by age group)
22 737/66 796/100 




n (%) n (%) n (%) n (%) n (%)
Pre- diabetes
Age (years)
  40–44 118 (0.5) 28 (4.0) 33 (4.9) 2 (1.3) 181 (0.7)
  45–54 1001 (1.5) 97 (7.0) 185 (12.2) 9 (2.5) 1292 (1.8)
  55–64 3692 (3.7) 186 (16.8) 157 (20.6) 41 (14.1) 4076 (4.0)
  65–74 2416 (5.9) 72 (20.1) 77 (28.7) 9 (14.8) 2574 (6.1)
Undiagnosed diabetes
  40–44 30 (0.1) 8 (1.1) 6 (0.9) 0 (0) 44 (0.2)
  45–54 183 (0.3) 39 (2.8) 36 (2.4) 3 (0.8) 261 (0.4)
  55–64 588 (0.6) 52 (4.7) 32 (4.2) 7 (2.4) 679 (0.7)
  65–74 303 (0.7) 17 (4.7) 16 (6.0) 1 (1.6) 337 (0.8)
Pre- diabetes or undiagnosed diabetes
  40–44 148 (0.7) 36 (5.1) 39 (5.8) 2 (1.3) 225 (0.9)
  45–54 1184 (1.8) 136 (9.8) 221 (14.6) 12 (3.4) 1553 (2.2)
  55–64 4280 (4.3) 238 (21.5) 189 (24.8) 48 (16.5) 4755 (4.6)
  65–74 2719 (6.6) 89 (24.8) 93 (34.7) 10 (16.3) 2911 (6.9)
  Yield Yield Yield Yield Yield
Pre- diabetes
  40–44 1 in 200 1 in 25 1 in 20 1 in 77 1 in 143
  45–54 1 in 67 1 in 14 1 in 8 1 in 40 1 in 56
  55–64 1 in 27 1 in 6 1 in 5 1 in 7 1 in 25
  65–74 1 in 17 1 in 5 1 in 4 1 in 7 1 in 16
Undiagnosed diabetes
  40–44 1 in 1000 1 in 91 1 in 111 N/A 1 in 500
  45–54 1 in 333 1 in 36 1 in 42 1 in 125 1 in 250
  55–64 1 in 167 1 in 21 1 in 24 1 in 42 1 in 143
  65–74 1 in 143 1 in 21 1 in 17 1 in 63 1 in 125
Pre- diabetes or undiagnosed diabetes
  40–44 1 in 143 1 in 20 1 in 17 1 in 77 1 in 111
  45–54 1 in 56 1 in 10 1 in 7 1 in 30 1 in 46
  55–64 1 in 23 1 in 5 1 in 4 1 in 6 1 in 22
  65–74 1 in 15 1 in 4 1 in 3 1 in 6 1 in 15
Yield refers to the average number needing to be tested to identify one case.
HbA1c, glycated hemoglobin; n, number; N/A, not available.
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a score would identify those at higher risk of prevalent 
diabetes and therefore at higher risk of being in the 
pre- diabetes stage since there is a continuum of risk.
The benefit of detecting those at higher risk of diabetes 
to delay or prevent conversion to frank diabetes has been 
widely accepted. Follow- up of earlier prevention studies 
has now shown that diabetes prevention lessens cardio-
vascular outcomes and lowers mortality risk.17 While most 
such studies used oral glucose tolerance test- based criteria 
to determine those at elevated risk of diabetes, higher 
HbA1c levels are well accepted in predicting incident 
cardiovascular disease18 and microvascular damage,19 at 
least as well as other glycemia measures. As HbA1c can 
be done any time of the day, irrespective of fasting status, 
it is a more feasible test for widespread community- based 
adoption.
Of course, HbA1c is more expensive than blood glucose 
and so its use for screening purposes should be weighed 
carefully against the cost of mass testing. That noted, 
given that one in six individuals of black ethnicity or one 
Table 5 Crude prevalence of pre- diabetes and undiagnosed diabetes and crude yield of HbA1c in the UK Biobank in men by 
age and ethnic group
White South Asian Black Chinese Overall
n=19 399/51 436/79 
274/38 262 n=897/1445/1042/457 n=590/1042/538/198 n=104/205/145/44
n=20 990/54 128/80 
999/38 961
n (%) n (%) n (%) n (%) n (%)
Pre- diabetes
Age (years)
  40–44 187 (1.0) 58 (6.5) 49 (8.3) 8 (7.7) 302 (1.4)
  45–54 1062 (2.1) 148 (10.2) 125 (12.0) 7 (3.4) 1342 (2.5)
  55–64 3156 (4.0) 152 (14.6) 102 (19.0) 22 (15.2) 3432 (4.2)
  65–74 2212 (5.8) 74 (16.2) 42 (21.2) 8 (18.2) 2336 (6.0)
Undiagnosed diabetes
  40–44 104 (0.5) 22 (2.5) 9 (1.5) 0 (0) 135 (0.6)
  45–54 404 (0.8) 61 (4.2) 31 (3.0) 1 (0.5) 497 (0.9)
  55–64 849 (1.1) 44 (4.2) 22 (4.1) 2 (1.4) 917 (1.1)
  65–74 440 (1.1) 20 (4.4) 15 (7.8) 1 (2.3) 476 (1.2)
Pre- diabetes or undiagnosed diabetes
  40–44 291 (1.5) 80 (8.9) 58 (9.8) 8 (7.7) 437 (2.1)
  45–54 1466 (2.9) 209 (14.5) 156 (15.0) 8 (3.9) 1839 (3.4)
  55–64 4005 (5.1) 196 (18.8) 124 (23.1) 24 (16.6) 4349 (5.4)
  65–74 2652 (6.9) 94 (20.6) 57 (28.8) 9 (20.5) 2812 (7.2)
  Yield Yield Yield Yield Yield
Pre- diabetes
  40–44 1 in 100 1 in 15 1 in 12 1 in 13 1 in 71
  45–54 1 in 48 1 in 10 1 in 8 1 in 29 1 in 40
  55–64 1 in 25 1 in 7 1 in 5 1 in 7 1 in 24
  65–74 1 in 17 1 in 6 1 in 5 1 in 6 1 in 17
Undiagnosed diabetes
  40–44 1 in 200 1 in 40 1 in 67 N/A 1 in 48
  45–54 1 in 125 1 in 24 1 in 33 1 in 200 1 in 29
  55–64 1 in 91 1 in 24 1 in 24 1 in 71 1 in 19
  65–74 1 in 91 1 in 23 1 in 13 1 in 44 1 in 14
Pre- diabetes or undiagnosed diabetes
  40–44 1 in 67 1 in 11 1 in 10 1 in 13 1 in 48
  45–54 1 in 35 1 in 7 1 in 7 1 in 26 1 in 29
  55–64 1 in 20 1 in 5 1 in 4 1 in 5 1 in 19
  65–74 1 in 15 1 in 5 1 in 4 1 in 6 1 in 14
Yield refers to the average number needing to be tested to identify one case.
HbA1c, glycated hemoglobin; n, number; N/A, not available.
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in seven of South Asian ethnicity in the 40–70 year- old age 
ranges have actionable HbA1c levels, it would potentially 
make widespread HbA1c testing in these populations 
cost- effective, and especially if in addition to preventing 
some progressing to diabetes, it is also possible to iden-
tify and treat those with undiagnosed diabetes. Many 
people are still not diagnosed until the development of 
serious complications. The importance of identifying 
people with undiagnosed diabetes is reinforced by the 
emergence of evidence- based approaches to diabetes 
remission and earlier intervention with pharmacological 
therapies that reduce the risk of progression of complica-
tions. That UK Biobank does not cover people older than 
70 years of age may be seen as a limitation; however, it is 
notable that those with younger- onset type 2 diabetes lose 
more life years from diabetes than those who develop it 
when much older.20 Therefore, there is greater merit in 
identifying younger people at risk of diabetes or with 
undiagnosed diabetes.
While there are debates about the use of HbA1c in different 
ethnicities, important data from the Outcome Reduction 
with Initial Glargine Intervention (ORIGIN) trial of 12 527 
people reported that the strong relationship between A1C 
and fasting plasma glucose (FPG) in people with moderate 
dysglycemia (5.6–9.0 mmol/L) is not significantly affected 
by ethnic or geographical differences.21 This range includes 
those with pre- diabetes, and as such the findings lend strong 
confidence that HbA1c levels in different ethnicities reflect 
similar dysregulation in glycemia levels.
In the UK, risk screening is supposed to link a risk 
score to identify those at highest risk, followed by formal 
glycemia testing either in fasted state (using fasting 
glucose) or any time of the day (HbA1c) in those with 
higher diabetes risk scores. Our work suggests that 
such risk scores may not be needed for middle- aged 
and old- aged South Asian or black individuals in whom 
the yield appears sufficiently high to consider single- 
stage mass screening using HbA1c. However, further 
studies are required to determine feasibility, uptake, and 
cost- effectiveness.
The work has some notable strengths, with the size and 
coverage of the study surpassing all prior studies in this 
area. Even so, we accept there are some limitations to our 
study. The sociodemographic representativeness of the 
UK Biobank is not identical to the general population.22 
We addressed this partially by standardizing our esti-
mates against the UK general population in terms of age, 
sex, and ethnic group distribution and we obtained very 
similar results. However, estimates of prevalence in the 
UK general population should still be taken with caution, 
as UK Biobank participants are less likely to be from a 
deprived area, less likely to be obese and to have a better 
lifestyle, and there is evidence of a ‘healthy volunteer’ 
selection bias.22 Indeed, it may be that the UK Biobank 
underestimates glycemia risks in some ethnicities. We 
had insufficient statistical power to include some ethnic 
groups, such as Arabs, and were obliged to amalgamate 
others. HbA1c values were also not available in a small 
proportion of people, but the level of missing data was 
comparable between ethnic groups and is unlikely to be 
systematic. We also recognize that HbA1c can sometimes 
be erroneous in people with certain hemoglobinopa-
thies, but notably hemoglobin A1c was reportable in the 
presence of HbS, HbC, HbD, and HbE traits for the assay 
method used in the UK Biobank. We also recognize the a 
cut- off age of 40 years old means that younger people at 
risk of undiagnosed diabetes are not captured, but even 
so the results in other age groups should still be valid. 
Finally, the distribution of HbA1c was positively skewed 
and it is possible that those in the lower ranges of the 
HbA1c could be a dynamic group that may revert into 
‘normal’ ranges.
We conclude that HbA1c is extremely efficient at iden-
tifying pre- diabetes and undiagnosed diabetes in middle- 
aged and old- aged South Asian and black individuals. 
Therefore, consideration should be given to single- stage 
mass screening of these high- risk populations using 
HbA1c.
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Supplemental Table S1. Crude prevalence of pre- and undiagnosed diabetes and crude yield of HbA1c in UK Biobank by ethnic 











      
 N (%) N (%) N (%) N (%) N (%) 
Pre-diabetes 11,807 (3.0)  712 (10.3)  713 (13.3)  103 (7.7) 13,335 (3.2) 
Undiagnosed diabetes 2,532 (0.6)  239 (3.4)  154 (2.9)  15 (1.1)  2,940 (0.7) 
Pre- or undiagnosed diabetes 14,339 (3.6) 951 (13.7) 867 (16.2) 118 (8.8) 16,275 (4.0) 
      
 Yield Yield Yield Yield Yield 
Pre-diabetes 1 in 34 1 in 10 1 in 8 1 in 13 1 in 31 
Undiagnosed diabetes 1 in 157 1 in 29 1 in 35 1 in 89 1 in 140 
Pre- or undiagnosed diabetes 1 in 28 1 in 7 1 in 6 1 in 11 1 in 25 
N: number 
Yield: Average number needing to be tested to identify one case  
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Supplementary Table S2. Association between ethnic groups and pre- and undiagnosed diabetes 
Prediabetes 
Model 1 
OR (95% CI) P value 
Model 2 
OR (95% CI) P value 
          
White 1 Referent   1 Referent   
South Asian 3.63 (3.36-3.91) <0.001 5.33 (4.90-5.80) <0.001 
Black 4.69 (4.34-5.07) <0.001 5.43 (4.96-5.94) <0.001 
Chinese 2.47 (2.02-3.01) <0.001 5.66 (4.58-6.99) <0.001 
          
Undiagnosed diabetes         
          
White 1 Referent   1 Referent   
South Asian 5.29 (4.65-6.02) <0.001 7.05 (6.11-8.14) <0.001 
Black 4.43 (3.78-5.19) <0.001 4.00 (3.37-4.76) <0.001 
Chinese 1.60 (0.98-2.66) 0.073 4.41 (2.63-7.39) <0.001 
 
OR Odds ratio; CI confidence interval 
Model1: Unadjusted 
Model 2: Adjusted for sociodemographic factors  (sex, age, deprivation), BMI and lifestyle score, at baseline 
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